<DOC>
	<DOC>NCT00354341</DOC>
	<brief_summary>This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patients &gt;=18 years of age; type 1 or type 2 diabetes; stable glycemic control for &gt;=3 months; diabetic nephropathy. women who are pregnant, breastfeeding, or unwilling to use a reliable contraceptive method; previous treatment with erythropoietin or other erythropoietic substance; nondiabetic renal disease, nephrotic syndrome; blood transfusion within the 3 months prior to enrollment; administration of any investigational drug within 30 days preceding the study start, and during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>